Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Death Reported In Phase II Trial For Astellas/FibroGen's Oral EPO Candidate

This article was originally published in PharmAsia News

Executive Summary

Astellas/FibroGen have observed one fatality in a Phase II trial of the oral anemia treatment candidate FG-2216, Astellas reported May 7. The cause of death was fulminant hepatitis, and FDA has been notified

You may also be interested in...



AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself

In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.

Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.

Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo

Astellas Backed By Full Pipeline To Battle Japan Price Controls and Slow Approvals In U.S.

Astellas' user fee date for immunosuppressant Prograf MR (tacrolimus) NDA pending at the U.S. FDA has been extended for another three months, the company told a third quarter earnings call Feb.1 at its headquarters in Tokyo

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel